AAV-TERT-04

AAV-TERT-04 is an adeno-associated virus (AAV) gene therapy candidate currently in the discovery stage of development by Telomere Therapeutics. The therapy is designed to deliver and express the telomerase reverse transcriptase (TERT) gene in adult tissues. By promoting telomerase expression, the therapy aims to counteract telomere shortening, a biological process linked to cellular senescence and various degenerative diseases. While Telomere Therapeutics' lead program (AAV-TERT-01) is focused on idiopathic pulmonary fibrosis (IPF), the specific therapeutic indication for AAV-TERT-04 has not yet been disclosed. The company's pipeline is based on the research of co-founders María A. Blasco and Fàtima Bosch, who are experts in telomere biology and AAV-mediated gene delivery.